Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of progression to acute myeloid leukaemia (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron overload. In β-thalassaemia major, transfusional iron overload leads to organ dysfunction and death; however, with iron chelation therapy, organ function is improved, and survival improved to near normal and correlated with the degree of compliance with chelation. In lower-risk MDS, several nonrandomized studies suggest an adverse effect of iron overload on survival and that lowering iron with chelation may minimize this impact. Emerging data indicate that chelation may improve organ function, particularly hepatic function, and a minority of patients may have improvement in cell counts and decreased transfusion requirements. While guidelines for MDS generally recommend chelation in selected lower-risk patients, data from nonrandomized trials suggest iron overload may impact adversely on the outcome of higher-risk MDS and stem cell transplantation (SCT). This effect may be due to increased transplant-related mortality, infection and AML progression, and preliminary data suggest that lowering iron may be beneficial in this patient group. Other areas of active and future investigation include optimizing the monitoring of iron overload using imaging such as T2* MRI and measures of labile iron and oxidative stress; correlating new methods of measuring iron to clinical outcomes; clarifying the contribution of different cellular and extracellular iron pools to iron toxicity; optimizing chelation by using agents that access the appropriate iron pools to minimize the relevant clinical consequences in individual patients; and incorporating measures of quality of life and co-morbidities into clinical trials of chelation in MDS. It should be noted that chelation is costly and potentially toxic, and in MDS should be initiated after weighing potential risks and benefits for each patient until more definitive data are available. In this review, data on the impact of iron overload in MDS and SCT are discussed; for example, several noncontrolled studies show inferior survival in patients with iron overload in these clinical settings, including an increase in transplant-related mortality and infection risk. Possible mechanisms of iron toxicity include oxidative stress, which can damage cellular components, and the documented impact of lowering iron on organ function with measures such as iron chelation therapy includes an improvement in elevated liver transaminases. Lowering iron also appears to improve survival in both lower-risk MDS and SCT in nonrandomized studies. Selected aspects of iron metabolism, transport, storage and distribution that may be amenable to future intervention and improved removal of iron from important cellular sites are discussed, as are attempts to quantify quality of life and the importance of co-morbidities in measures to treat MDS, including chelation therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased inflammatory activity with reduced intestinal absorption of Fe, with stronger sequestration of Fe in macrophages and lowered Fe, are reflected in the serum, which, at the same time, shows an increase in serum ferritin levels [88,89,90].”
From Iron Deficiency in Obesity and after Bariatric Surgery (2021) · cites this paper as [88]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 19×
“[54] Anaemia impacts on mortality and disability in patients without[93] and with MDS,[65] and may increase cardiac output, lead to left ventricular hypertrophy and exacerbate coronary syndromes.”
InfluentialGoycoolea, A. (1997) · Cited by 3,615
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
Anderson, L. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2822 · Cited by 1,682
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Research works printed but not linked: 16
- Alessandrino, 2002, Haematologica, 87, 1286
- Malcovati, 2006, Haematologica, 91, 1588
- Borgna-Pignatti, 2004, Haematologica, 89, 1187
- Jaeger, 1992, Beitr Infusionsther, 30, 464
- Mathew, 1993, Blood, 81, 1040, 10.1182/blood.V81.4.1040.1040 · doi:10.1182/blood.v81.4.1040.1040
- Del Río Garma, 1997, Haematologica, 82, 639
- Okabe, 2009, Rinsho Ketsueki, 50, 1626
- Smeets, 1996, Am J Hematol, 51, 243, 10.1002/(SICI)1096-8652(199603)51:3<243::AID-AJH12>3.0.CO;2-H · doi:10.1002/(sici)1096-8652(199603)51:3<243::aid-ajh12>3.0.co;2-h
- Hann, 1988, Cancer Res, 48, 4168
- McKay, 1996, Bone Marrow Transplant, 17, 63
- Gattermann, 2005, Hematol Oncol Clin North Am, 19, 18
- Mittelman, 2008, Isr Med Assoc J, 10, 374
- Borgna-Pignatti, 1998, Haematologica, 83, 788
- Franchini, 2004, Blood, 103, 747, 10.1182/blood-2003-10-3373 · doi:10.1182/blood-2003-10-3373
- Porter, 1998, Blood, 92, 668a
- Yarali, 2006, J Pediatr Hematol Oncol, 28, 11
Cited by
Shenoy, N. K., Vallumsetla, N., Rachmilewitz, E. A., Verma, A., & Ginzburg, Y. Z. (2014) · Blood · doi:10.1182/blood-2014-03-563221 · Cited by 141
Infections in myelodysplastic syndromes
Toma, A., Fenaux, P., Dreyfus, F., & Cordonnier, C. (2012) · Haematologica · doi:10.3324/haematol.2012.063420 · Cited by 133
Iron Deficiency in Obesity and after Bariatric Surgery
Bjørklund, G., Peana, M., Pivina, L., Dosa, A., Aaseth, J., Semenova, Y., Chirumbolo, S., Medici, S., Dadar, M., & Costea, D.-O. (2021) · Biomolecules · doi:10.3390/biom11050613 · Cited by 99
On behalf of the IRON-2 Study Group, Remacha, A. F., Arrizabalaga, B., Villegas, A., Durán, M. S., Hermosín, L., de Paz, R., García, M., Díez‐Campelo, M., & Sanz, G. F. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2274-y · Cited by 63
“The increased risk of progression to acute myeloid leukemia under conditions of oxidative stress, characteristic of iron overload, has been validated by indirect data from preclinical studies showing the effect of iron modifying cell growth and differentiation [32].”
BackgroundNew insights into transfusion-related iron toxicity: Implications for the oncologist
Porter, J. B., de Witte, T., Cappellini, M. D., & Gattermann, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.017 · Cited by 59
“Some tissues tolerate higher levels of iron overload, and associated labile cellular iron and ROS, than others; for example, tissue iron concentrations tolerated by the liver (Leitch, 2011) are highly toxic to the heart (Leitch, 2011; Carpenter et al.”
Background
Metadata
- Authors
- Leitch, H. A.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Leitch, Heather A.
- ORCID
- Leitch, Heather A.
- Venue
- Drugs
- Published
- 2011-01
- Volume
- 71
- Issue
- 2
- Pages
- 155-177
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2219541779
- Cited by
- 17
- References
- 224
- Citations by year
- 2021: 2 · 2020: 2 · 2018: 1 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 3
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- myelodysplastic syndrome, transfusional iron overload, iron chelation therapy, beta-thalassaemia major, stem cell transplantation, non-relapse mortality, oxidative stress, iron toxicity, liver function, T2-weighted MRI, labile plasma iron, iron metabolism, survival outcomes, transfusion requirements, quality of life
- MeSH terms
- Clinical Trials as Topic, Humans, Iron, Iron Chelating Agents, Models, Biological, Myelodysplastic Syndromes, Quality of Life, Tissue Distribution, Chelation Therapy, Iron Overload, Transfusion Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments. https://app.cochat.ai/papers/10.2165/11585280-000000000-00000
- The paper
- Leitch, H. A. (2011). Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments. Drugs. https://doi.org/10.2165/11585280-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.